Clinical Trial Update: Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 study comparing the efficacy and safety of brolucizumab versus aflibercept in Chinese patients with Neovascular Age-Related Macular Degeneration; trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• BEOVU (BROLUCIZUMAB)
• EYLEA (Aflibercept)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-Related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2024-12-09